Publications

Schinke C, Touzeau C, Oriol A, Mateos MV, Stevens D, Rasche L, Moreau P, San-Miguel J, Rodríguez-Otero P, Kato K, Bathija S, Katz EG, Masterson T, Tomlinson C, Chari A. A plain language summary describing how talquetamab affects the way people with multiple myeloma feel and function in the MonumenTAL-1 study. Future oncology (London, England). 2026. PMID: 42299486

Lombardi P, Ramon-Gil E, Raja RQ, Brunetti L, Manfredi GF, Zhou Z, Merces G, Cappuyns S, Fulgenzi CAM, D'Alessio A, Torkpour A, Celsa C, Stefanini B, Yang H, Crowley F, Marron TU, Saeed A, Pinter M, Scheiner B, Huang YH, Lee PC, Nishida N, Po-Ting Lin R, Dalbeni A, Vivaldi C, Masi G, Rohlen N, von Felden J, Kaseb A, Galle PR, Kudo M, Hsu WF, Rimassa L, Parisi A, Kelley RK, Toyoda H, Pirisi M, Jabar F, Rakaee M, Cabibbo G, Cammà C, Piscaglia F, Hwang S, Shin DJ, Li M, Dekervel J, Guerra N, Meyer T, Reeves HL, Bengsch B, Daniele G, Mann DA, Chon HJ, Leslie J, Pinato DJ. A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab plus bevacizumab in hepatocellular carcinoma. Journal of hepatology. 2026. PMID: 42297215

Llovet JM, Mauro E, Rimassa L, Mazzaferro V, Pinter M, Kelley RK, Chan SL, Kulik L, Pillai A, Roberts L, Sangro B, Casanovas T, Kaplan DE, Vogel A, Yarchoan M, Finn RS, Meyer T, Singal AG. Trial design and end points in hepatocellular carcinoma: an EASL-AASLD-ILCA consensus statement. Nature reviews. Clinical oncology. 2026. PMID: 42270817

Zwart K, van Kruijsdijk RCM, Nagtegaal ID, Bol GM. Reply to "Reassessing the evidence for elevated deficient mismatch repair colorectal cancer risk after kidney transplantation". American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2026. PMID: 42269873

Kimambo AH, Vuhahula E, Mmbaga EJ, Baraka BM, Malango A, Illonga Z, Mushi BP, Kitosho B, Van Loon K, Ng DL. Contextual Barriers and Facilitators to Implementing Ultrasound-Guided Fine-Needle Aspiration and Rapid Onsite Evaluation in a Resource-Limited Setting. JCO global oncology. 2026. PMID: 42269133

Mennillo E, Lotstein ML, Lee G, Hou JH, Johri V, Leet DE, Ekstrand CA, Tsui J, He JY, Mahadevan U, Eckalbar WL, Gill RM, Bowman CJ, Oh DY, Fragiadakis GK, Kattah MG, Combes AJ. Single-cell spatial transcriptomics of formalin-fixed, paraffin-embedded biopsies reveals colitis-associated cell networks. The Journal of clinical investigation. 2026. PMID: 42262875

Zeng J, Cheng Z, Chen H, Wang Z, Thompson J, Crosby KT, Han H, Singhal A, Ngo W, Xia C, Rosas-Rivera D, Zhang Z, Kang MH, Mao Y, Diolaiti ME, Lee GC, Diffley JFX, Song Y, Qiu L, Krah NM, Murthy N, Jackson RN, Liu Y, Ashworth A, Doudna JA. Targeting Cancer-Specific Mutations with RNA-Triggered Chromatin Shredding. Nature. 2026. PMID: 42259916

Lipof J, Bloudek B, Ray A, Ting J, Hasegawa K, Gong C, Williams T, Ramsey S, Chari A. Impact of Treatment Sequencing With CAR T-cell Therapies and Bispecific Antibodies on Long-term Survival in 4L+ RRMM in the United States: A Simulation Model. Clinical lymphoma, myeloma & leukemia. 2026. PMID: 42342528

Wong P, Pollini T, Hernandez S, Tao S, Qiao G, Amouzegar A, Bol GM, Daud AI, Tao DL, Tsai KK, Lee J, Maker AV. The paradox of escalating immunotherapy for uveal melanoma liver metastases. HPB : the official journal of the International Hepato Pancreato Biliary Association. 2026. PMID: 42315386

Rugo HS, Curigliano G, Cescon DW, Penault-Llorca F, Harbeck N, Im SA, Park YH, Barrios C, Modi S, Tolaney SM, Oliveira M. New perspectives on endocrine therapy suitability for hormone receptor-positive metastatic breast cancer in clinical practice. Breast (Edinburgh, Scotland). 2026. PMID: 42263382

Chatterjee A, Mustafa Ali MK, Bailey CM, Liu Y, Small D, Smith CC, Traer E, Wang Y, Silvestri G, Baer MR. Sphingosine-1-phosphate receptor modulators resensitize FLT3-ITD acute myeloid leukemia cells with NRAS mutations to FLT3 inhibitors. Leukemia. 2026. PMID: 42230959

Harris CS, Tsai KK, Liu L, Oppegaard KR, Cooper BA, Paul SM, Hubbard EM, Levine JD, Miaskowski CA. Study Protocol to Characterize Symptom Experience During Immune Checkpoint Inhibitor Therapy for Cutaneous Melanoma. Nursing research. 2026. PMID: 42228432

Raleigh D, Cady M, Aggarwal A, Stevers N, Zakimi N, Liu I, Mirchia K, Coukos J, Kongpracha P, Zhou Y, Nguyen M, Braman B, Leclair N, Phillips J, Chow K, Shamdasani-Sen S, Chantousti N, Choi B, Hong C, Toedebusch R, Englander R, Frankus J, Sinha D, Karner H, Rosenbluth J, Veer LV', Choudhury A, Liu SJ, Krogan N, Costello J, Anczuków O, Toedebusch C, Dickinson P, Goodarzi H, Swaney D. A proteogenomic RNA processing mechanism drives sex differences in meningioma. Research square. 2026. PMID: 42282014

Berger JI, Anderson AD, Martinez OV, Morris MI, Raja M, Lekakis LJ, Beitinjaneh A, Jimenez A, Goodman M, Wang TP, Spiegel J, Holtzman NG, Komanduri KV, Pereira D, Green D, Camargo JF. Refractory and/or Resistant Herpes Simplex Virus Mucocutaneous Infections in Adult Transplantation and Cellular Therapy Patients: A Single-Center Experience. Cureus. 2026. PMID: 42395230

Aggarwal R, Oseran AS, Manrai AK, Marinacci LX, Bhatt DL, Yeh RW, Ho JE, Rodman A, Wadhera RK. Performance of Local Large Language Models for Adjudicating Heart Failure Hospitalizations. Circulation. 2026. PMID: 42224376

Kennedy VE, Peretz CAC, Walia A, Chyla B, Sun Y, Hill JE, Tran E, Koh AD, Ferng TT, Pintar S, Jones M, Popescu B, Lomeli I, Chehab F, Murad N, John A, Roy RP, Olshen AB, Berryhill CA, Davis C, Angus SP, Rivera JM, Meshulam A, Stieglitz E, Joshi SK, Traer E, Dail M, Hamidi H, Altman JK, Daver NG, Levis MJ, McCloskey J, Perl AE, Smith CC. Dynamic genetic and nongenetic RAS pathway activation drives resistance to FLT3 and BCL2 inhibitor therapy. Blood. 2026. PMID: 42224378

Swetter SM, Johnson D, Albertini MR, Barker CA, Bateni S, Baumgartner J, Bhatia S, Bichakjian C, Boland G, Chandra S, Chen D, Chmielowski B, Choi J, DiMaio D, Dronca R, Fleming MD, Galan A, Guild S, Hu-Lieskovan S, Karakousis G, Kendra K, Kiuru M, Lange JR, Lanning R, Logan T, Materin M, Nelson K, Olson D, Olszanski AJ, Ott PA, Puzanov I, Rothermel L, Salama AK, Shannon A, Sharma R, Singh A, Stacey A, Tsai K, Wuthrick E, Xing Y, McMillian N, Espinosa S. Melanoma: Cutaneous, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 2026. PMID: 42297031

McConathy J, Koshkin VS, Menda Y, Rodon J, Goenka AH, Moy RH, Morse S, Demange A, Blumenstein L, Babaoglan B, Aimone P, Hope TA. Targeting Fibroblast Activation Protein with [177Lu]Lu-FAP-2286 in Patients with Advanced Solid Tumors in the Phase I LuMIERE Trial. Clinical cancer research : an official journal of the American Association for Cancer Research. 2026. PMID: 42223513

Pollyea DA, Altman JK, Assi R, Bachiashvili K, Bhatt VR, Fathi AT, Fedorov K, Foran JM, Gojo I, Goldberg A, Hall AC, Jonas BA, Levine MR, Mangan J, Mannis G, Marcucci G, Mims A, Moriarty K, Mustafa Ali M, Neff J, Nejati R, Olin R, Patel A, Percival ME, Perl A, Pettit K, Rao D, Ravandi F, Schwabkey Z, Shallis R, Stahl M, Stone RM, Thota S, Uy GL, Walker A, Wang E, Awotiwon A, Roth SL, Stehman K. NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026. Journal of the National Comprehensive Cancer Network : JNCCN. 2026. PMID: 42297017

Beumer A, Carlson M, Arcuri AL, Maues J, Cowden J, Walker S, Shanahan K, Collins JL, Veach AJ, Rugo HS, Burkard ME, Kalinsky KM, Bardia A, Lustberg MB, Papautsky EL, Roberson ML. A Patient-Led Survey of Antibody Drug Conjugate Usage and Dosing for People Living With Metastatic Breast Cancer. Journal of Patient Experience. 2026. PMID: 42227000